Showing results (41-50 of 92) with videos related to
Sort By:
Pageof 10
Cancer Letters|July 11, 2012
Mammary fibroblasts regulate morphogenesis of normal and tumorigenic breast epithelial cells by mechanical and paracrine signalsInke Lühr, Andreas Friedl, Thorsten Overath, et al.Journal of the National Cancer Institute|July 18, 2013
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trialVolker Moebus, Christian Jackisch, Andreas Schneeweiss, et al.Cancers|August 25, 2019
Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto TrialMalgorzata Banys-Paluchowski, Sibylle Loibl, Isabell Witzel, et al.Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.Oncology|August 30, 2014
Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancerNicolai Maass, Christian Schem, Dirk O Bauerschlag, et al.International Journal of Cancer|March 6, 2024
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO studyDiana Lüftner, Florian Schuetz, Andreas Schneeweiss, et al.Journal of Bone Oncology|December 6, 2018
The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trialPeyman Hadji, Oliver Stoetzer, Thomas Decker, et al.Breast Cancer Research and Treatment|July 13, 2010
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trialIsabell Witzel, Sibylle Loibl, Gunter von Minckwitz, et al.International Journal of Cancer|July 12, 2018
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trialHans Tesch, Oliver Stoetzer, Thomas Decker, et al.Breast (Edinburgh, Scotland)|September 10, 2023
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)Thomas Decker, Kerstin Lüdtke-Heckenkamp, Luidmila Melnichuk, et al.Pageof 10